尽管 γδ T 细胞只包含一小群 T 细胞，但它们在预防感染和抑制肿瘤方面发挥着重要作用。凭借其独特的组织定位特性，结合其各种靶标识别机制，γδ T 细胞有潜力成为对当前治疗程序无反应的肿瘤的有效解决方案。其中一种肿瘤是胶质母细胞瘤（GBM），是世界卫生组织分级最高的恶性脑肿瘤，因此预后最差。免疫抑制性肿瘤微环境（TME）和免疫逃避性胶质瘤干细胞是GBM免疫治疗失败的主要因素。目前，受临床前和临床水平揭示的γδ T细胞强大的抗肿瘤功能的鼓舞，多个研究小组已经展示了基于γδ T细胞的GBM治疗的进展。然而，仍然存在一些限制，阻碍使用 γδ T 细胞进行有效的 GBM 治疗。因此，了解 γδ T 细胞在抗肿瘤免疫反应中的独特作用以及 GBM TME 的抑制机制对于成功的 γδ T 细胞介导的 GBM 治疗至关重要。在这篇综述中，我们总结了γδ T细胞在肿瘤免疫中的效应功能，并讨论了基于γδ T细胞的GBM免疫治疗的当前进展和局限性。此外，我们还提出了未来的方向，以克服基于 γδ T 细胞的 GBM 免疫疗法的局限性，以实现 GBM 的成功治疗。版权所有 © 2023 Kang、Kim 和 Lee。

Although γδ T cells comprise a small population of T cells, they perform important roles in protecting against infection and suppressing tumors. With their distinct tissue-localizing properties, combined with their various target recognition mechanisms, γδ T cells have the potential to become an effective solution for tumors that do not respond to current therapeutic procedures. One such tumor, glioblastoma (GBM), is a malignant brain tumor with the highest World Health Organization grade and therefore the worst prognosis. The immune-suppressive tumor microenvironment (TME) and immune-evasive glioma stem cells are major factors in GBM immunotherapy failure. Currently, encouraged by the strong anti-tumoral function of γδ T cells revealed at the preclinical and clinical levels, several research groups have shown progression of γδ T cell-based GBM treatment. However, several limitations still exist that block effective GBM treatment using γδ T cells. Therefore, understanding the distinct roles of γδ T cells in anti-tumor immune responses and the suppression mechanism of the GBM TME are critical for successful γδ T cell-mediated GBM therapy. In this review, we summarize the effector functions of γδ T cells in tumor immunity and discuss current advances and limitations of γδ T cell-based GBM immunotherapy. Additionally, we suggest future directions to overcome the limitations of γδ T cell-based GBM immunotherapy to achieve successful treatment of GBM.Copyright © 2023 Kang, Kim and Lee.